Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.

Gutiérrez C, Hernández-Novoa B, Vallejo A, Serrano-Villar S, Abad-Fernández M, Madrid N, Díaz L, Moreno A, Dronda F, Zamora J, Muñoz-Fernández MA, Moreno S.

AIDS. 2013 Aug 24;27(13):2081-8. doi: 10.1097/QAD.0b013e328361d0e1.

PMID:
24384589
[PubMed - indexed for MEDLINE]
2.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.

AIDS. 2012 Sep 24;26(15):1885-94.

PMID:
22992577
[PubMed - indexed for MEDLINE]
3.

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, Dahl V, Rubio R, Moreno AM, Dronda F, Casado JL, Navas E, Pérez-Elías MJ, Zamora J, Palmer S, Muñoz E, Muñoz-Fernández MÁ, Moreno S.

PLoS One. 2011;6(12):e27864. doi: 10.1371/journal.pone.0027864. Epub 2011 Dec 8.

PMID:
22174752
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.

Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; IntegRal Collaborative Group.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):152-60. doi: 10.1097/QAI.0b013e318289439a.

PMID:
23392458
[PubMed - indexed for MEDLINE]
5.

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J.

J Antimicrob Chemother. 2013 Oct;68(10):2358-62. doi: 10.1093/jac/dkt183. Epub 2013 May 14.

PMID:
23677919
[PubMed - indexed for MEDLINE]
Free Article
6.

HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.

Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK; PINT Study Team.

J Virol. 2014 Mar;88(6):3516-26. doi: 10.1128/JVI.03331-13. Epub 2014 Jan 8.

PMID:
24403590
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.

Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group.

AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066.

PMID:
24185044
[PubMed - indexed for MEDLINE]
8.

No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.

PMID:
22083073
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.

Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.

PMID:
22290239
[PubMed - indexed for MEDLINE]
10.

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW.

J Infect Dis. 2011 Dec 15;204(12):1936-45. doi: 10.1093/infdis/jir667. Epub 2011 Oct 21.

PMID:
22021620
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Pierson T, McArthur J, Siliciano RF.

Annu Rev Immunol. 2000;18:665-708. Review.

PMID:
10837072
[PubMed - indexed for MEDLINE]
12.

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.

AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.

PMID:
22089379
[PubMed - indexed for MEDLINE]
13.

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG.

J Infect Dis. 2013 Nov 1;208(9):1436-42. doi: 10.1093/infdis/jit453. Epub 2013 Aug 23.

PMID:
23975885
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG.

J Infect Dis. 2013 Oct 15;208(8):1202-11. doi: 10.1093/infdis/jit311. Epub 2013 Jul 12.

PMID:
23852127
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.

Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, Gilman LE, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG.

Blood. 2013 Jun 6;121(23):4635-46. doi: 10.1182/blood-2012-06-436345. Epub 2013 Apr 15.

PMID:
23589670
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F.

Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.

PMID:
20156060
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG.

J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138.

PMID:
21402547
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR.

J Infect Dis. 2012 Aug 15;206(4):534-42. doi: 10.1093/infdis/jis376. Epub 2012 Jun 27.

PMID:
22740718
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.

Gandhi RT, Bosch RJ, Aga E, Bedison MA, Bastow B, Schmitz JL, Siliciano JD, Siliciano RF, Eron JJ, Mellors JW; ACTG A5173 team.

Antivir Ther. 2013;18(4):607-13. doi: 10.3851/IMP2543. Epub 2013 Feb 15.

PMID:
23411421
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.

Massanella M, Negredo E, Puig J, Puertas MC, Buzón MJ, Pérez-Álvarez N, Carrillo J, Clotet B, Martínez-Picado J, Blanco J.

AIDS. 2012 Nov 28;26(18):2285-93. doi: 10.1097/QAD.0b013e328359f20f.

PMID:
23018435
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk